Structural definition of a potent macrophage activating factor derived from vitamin D3-binding protein with adjuvant activity for antibody production

Molecular Immunology

Volumn 33, Issue 15, 1996, Pages 1157-1164

  Yamamoto, Nobuto ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

Author keywords

antibody secretion; glycosidases; lectins; macrophage activating factor; phagocytosis; vitamin D binding protein

Indexed keywords

BETA GALACTOSIDASE; IMMUNOLOGICAL ADJUVANT; LECTIN; MACROPHAGE ACTIVATING FACTOR; SIALIDASE; VITAMIN D BINDING PROTEIN;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; FEMALE; MACROPHAGE; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SPLEEN CELL;

ADJUVANTS, IMMUNOLOGIC; ADOPTIVE TRANSFER; ANIMALS; ANTIBODY FORMATION; ANTIBODY-PRODUCING CELLS; BETA-GALACTOSIDASE; CELL COUNT; ERYTHROCYTES; FEMALE; HUMANS; MACROPHAGE-ACTIVATING FACTORS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; NEURAMINIDASE; SHEEP; TIME FACTORS; VITAMIN D-BINDING PROTEIN;

EID: 0030268364     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(96)00081-8     Document Type: Article

References (31)

1. Bianco C., Griffin F. M. and Silverstein S. C. (1975) Studies of the macrophage complement receptors. Alternative of receptor function upon macrophage activation. J. Exp. Med. 141, 1278-1290.
2. Cooke N. E. and Haddad J. G. (1989) Vitamin D binding protein (Gc-globulin). Endocrine Rev. 10, 294-307.
3. Homma S., Millman I. and Yamamoto N. (1990) Serum factor for macrophage activation after in vitro dodecylglycerol treatment of mouse lymphocytes. Immun. Cell Biol. 68, 137-142.
4. Homma S. and Yamamoto N. (1990) Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin. Exp. Immun. 79, 307-313.
5. Homma S., Yamamoto M. and Yamamoto N. (1993) Vitamin D binding protein (Group-specific component) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immun. Cell Biol. 71, 249-257.
6. Jerne N. K., Nordin A. A. and Henry C. (1963) The Agar Plaque Technique for Recognizing Antibody Producing Cells. (Edited by B. Amos and H. Koprowski) Cell-bound antibody PIC9. Wistar Institute Press, Philadelphia.
7. 3-binding protein-derived macrophage activating factor. Am. Assoc. Cancer Res. Proc. 37, 481.
8. 3-Sepharose chromatography. Anal. Biochem. 157, 262-269.
9. 3-binding protein-derived macrophage activating factor. Am. Assoc. Cancer Res. Proc. 37, 213.
10. Naraparaju V. R. and Yamamoto N. (1994) Roles of β-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immun. Lett. 43, 143-148.
11. Ngwenya B. Z. and Yamamoto N. (1985) Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim. Biophys. Acta 839, 9-15.
12. Ngwenya B. Z. and Yamamoto N. (1986) Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immun. Immunother. 21, 174-182.
13. Ngwenya B. Z. and Yamamoto N. (1990) Contribution of lysophosphatidylcholine-treated nonadherent cells to mechanism of macrophage activation. Proc. Soc. Exp. Biol. Med. 193, 118-124.
14. Svasti J. and Bowman B. H. (1978) Human group-specific component changes in electrophoretic mobility resulting from vitamin D binding and from neuraminidase digestion. J. Biol. Chem. 253, 4188-4194.
15. Viau M., Constans J., Debray H. and Montreuil J. (1983) Isolation and characterization of the o-glycan chain of the human vitamin D-binding protein. Biochem. Biophys. Res. Comm. 117, 324-331.
16. 3 binding protein (group-specific component) is a precursor for the macrophage activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc. natn. Acad. Sci. U.S.A. 88, 8539-8543.
17. 3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunology 74, 420-424.
18. 3 binding protein (Group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J. Immun. 147, 273-280.
19. 3 binding protein (Group-specific component) to a macrophage activating factor by the stepwise action of β-galactosidase of B cells and sialidase of T cells. J. Immun. 151, 2794-2902.
20. 3-binding protein and albumin. Infect. Immun. 61, 5388-5891.
21. Yamamoto N., Lindsay D. D., Naraparaju V. R., Ireland R. A. and Popoff S. N. (1994a) A defect in the inflammation-primed macrophage activation cascade in osteopetrotic (op) rats. J. Immun. 152, 5100-5107.
22. Yamamoto N. and Naraparaju V. R. (1996a) A defect in β-galactosidase of B lymphocytes in the osteopetrotic (op/op) mouse. Immun. Lett. 50, 35-40.
23. Yamamoto N. and Naraparaju V. R. (1996b) A defect in inducible β-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse. Immunology 88, 604-610.
24. 3-binding protein in activation of macrophages. J. Immun. 157, 1744-1751.
25. 3-binding protein leads to immunosuppression in cancer patients. Cancer Res. 56, 2827-2831.
26. Yamamoto N., Naraparaju V. R. and Orchard P. J. (1996b) Defective lymphocyte glycosidases in the macrophage activation cascade of juvenile osteopetrosis. Blood 88, 1473-1478.
27. 3-binding protein and immunosuppression in AIDS patients. AIDS Res. Human Ret. 11, 1373-1378.
28. Yamamoto N. and Ngwenya B. Z. (1987) Activation of mouse peritoneal macrophages by lysophospholipids and ether derivatives of neutral lipids and phospholipids. Cancer Res. 47, 2008-2013.
29. Yamamoto N., Ngwenya B. Z., Sery T. W. and Pieringer P. A. (1987) Activation of macrophages by ether analogues of lysophospholipids. Cancer Immuno. Immunother. 25, 185-192.
30. Yamamoto N., St Claire D. A., Homma S. and Ngwenya B. Z. (1988) Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res. 48, 6044-6049.
31. Yamamoto N., Willett N. P. and Lindsay D. D. (1994b) Participation of serum proteins in the inflammation-primed activation of macrophages. Inflammation 18, 311-322.